本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Denali Therapeutics Inc.

15.50
+0.07000.45%
盤後15.500.00000.00%16:19 EDT
成交量:217.62萬
成交額:3,348.82萬
市值:22.66億
市盈率:-5.52
高:15.69
開:15.45
低:15.06
收:15.43
52周最高:33.33
52周最低:10.57
股本:1.46億
流通股本:1.32億
量比:0.70
換手率:1.65%
股息:- -
股息率:- -
每股收益(TTM):-2.8082
每股收益(LYR):-2.5705
淨資產收益率:-39.69%
總資產收益率:-24.99%
市淨率:2.21
市盈率(LYR):-6.03

資料載入中...

2024/08/20

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/08/20

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/08/20

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/08/20

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/08/20

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/08/13

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/08/13

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/08/01

重要事件披露

Form 8-K - Current report
2024/08/01

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/07/01

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/07/01

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/06/07

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/05/31

重要事件披露

Form 8-K - Current report
2024/05/08

季度報告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/05/07

重要事件披露

Form 8-K - Current report
2024/04/16

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/04/02

關聯方擬減持公告

Form 144 - Report of proposed sale of securities
2024/02/28

員工持股計劃

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/02/28

年度報告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2024/02/27

重要事件披露

Form 8-K - Current report